In subjects with liver diseases, such as NAFLD, GCGR resistance may affect this liver–α cell axis, as reduced hepatic GCGR expression or impaired GCGR signaling leads to decreased urea production, which, in turn, leads to hyperaminoacidemia and subsequent compensatory hyperglucagonemia. Here, GCGR is linked to liver disorder.